Article
Genetic polymorphisms in the mevalonate pathway affect the therapeutic response to alendronate treatment in postmenopausal Chinese women with low bone mineral density.
The pharmacogenomics journal - 1 Apr 2015
Wang C, Zheng H, He J-W, Zhang H, Yue H, Hu W-W, Gu J-M, Shao C, Fu W-Z, Hu Y-Q, Li M, Liu Y-J, Zhang Z-L
Abstract excerpt
Alendronate is an antiosteoporotic drug that targets the mevalonate pathway. To investigate whether the genetic variations in this pathway affect the clinical efficacy of alendronate in postmenopausal Chinese women with osteopenia or osteoporosis, 23 single-nucleotide polymorphisms (SNPs) in 7 genes were genotyped in 500 patients treated with alendronate for 12 months. Bone mineral density (BMD) was measured at...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.